Evaluating the readability of FDA-approved JAK inhibitor medication guides in dermatology

Arch Dermatol Res. 2025 Jan 8;317(1):200. doi: 10.1007/s00403-024-03742-2.

Abstract

Prior studies have highlighted significant challenges in the readability of patient educational materials in dermatology, which may represent a barrier to optimal treatment outcomes. As newer Janus kinase inhibitors (JAKi) gain FDA approval and are integrated into treatment regimens, it is crucial for patients to understand their usage, risks, and benefits. We evaluated the readability of FDA-approved JAKi medication guides to see if lessons from prior readability studies have been incorporated into these newer materials. Our analysis revealed that JAKi guides often exceed the sixth-grade readability level recommended by the American Medical Association. We found that the instructions on how to use the medication were more difficult to read than the discussion of side effects, a concerning disparity as proper medication administration prevents complications from misuse.

Keywords: FDA; Janus kinase inhibitor; Readability.

Publication types

  • Letter

MeSH terms

  • Comprehension*
  • Dermatology* / standards
  • Drug Approval
  • Humans
  • Janus Kinase Inhibitors* / therapeutic use
  • Patient Education as Topic*
  • Skin Diseases / drug therapy
  • United States
  • United States Food and Drug Administration*

Substances

  • Janus Kinase Inhibitors